|
|
||
|
|
|||
2015 International Symposium on Hematology & Oncology (ISHO) was held on 17, Oct., 2015 at Chang Yung-Fa Foundation,
Taipei, Taiwan, and was sponsored by BioLite, Inc. Prepared for more than a year, BioLite, Inc. invited world-renowned scientists
from the US, France, Japan and China in co-operation with the Hematology Society of Taiwan and College of Medicine of
National Taiwan University; with support from the Ministry of Science and Technology, the Ministry of Education, and also our partner
American BriVision Corporation (ABVC).
Dr. Pierre Fenaux talked about the pathogenesis of Myelodysplastic Syndrome (MSD). With extensive experience in real world MDS
treatments, he shared practical thoughts on current treatments.
Dr. Susanna Cunningham-Rundles shared about howβ-glucan signaling modulates immunity by stimulating cytokines and mentioned
that Maitake mushroom is one of the potential drug candidate.
Dr. Gary Deng is not only a scientist of Memorial Sloan Cancer Center (MSKCC) but also an expert of Traditional Chinese Medicine.
He presented several promising preclinical and early stage botanical drugs eg: curcumin and Maitake. You can search “About Herbs”
on the MSKCC website for more details and the recommended App.
After the symposium, BioLite, Inc. invited the scientists from Memorial Sloan Kettering Cancer Center to visit our R&D center in
Hsinchu Science Park to attend a Summit and advise our R&D results. Through the Summit, we shared new information about
botanical drug, and moreover, discussed about co-operation between BioLite, Inc. and two of the top cancer centers in the US.
Development of botanical drugs became a hot topic since Ms. Youyou Tu became the first Chinese medical researcher who won
the Nobel Prize in Physiology and Medicine.
BioLite, Inc. has been working on botanical drugs for around 10 years. BioLite, Inc. focuses on innovative botanical drugs with
high safety and low side effects for indications including CNS disorders, Myelodysplastic Symdrome, cancer combination therapy
and autoimmune diseases. BioLite, Inc. will continue developing botanical drugs to address unmet medical needs.
(Left to right)
Dr. Su-Peng Yeh, moderator of ISHO,
Dr. Ming-Chi Chang, moderator of ISHO,
Dr. Cheng Shyong Chang, moderator of ISHO,
Dr. Tzeon-Jye Ciou,
Dr. Dong-Tsamn Lin, President of Hematology Society of Taiwan,
Prof. Masao Tomonaga,
Dr. Susanna Cunningham-Rundles,
Dr. Tsung-Shann Jiang, Chairman of BioLite, Inc.,
Prof. Yun-Xian Chen,
Dr. Gary Deng,
Dr. Simon Yeung,
Dr. Webster Kiang, President of BioLite, Inc.,
Dr. Siqing Fu.